Novo Nordisk asks FDA to ban compounding pharmacies from making Ozempic, Wegovy copies
The Danish drugmaker Novo Nordisk argues that semaglutide, the active ingredient in Ozempic and Wegovy, are too complex for ...
Eli Lilly (LLY): A Leader in Pharmaceutical Innovation and Growth
Currently, financial markets are experiencing a mix of optimism and caution as investors react to changing economic ...
Smithsonian lands big donation for America's 250th birthday celebrations
The Smithsonian Institution has received a $40 million donation to support the museum group’s celebration of America’s 250th ...
US Medicaid programs say cost a key factor for weight-loss drug coverage, survey finds
Most U.S. states do not currently cover highly sought after weight-loss drugs from Novo Nordisk and Eli Lilly in their ...
UK approves Lilly's Alzheimer's drug, but deemed 'too expensive' for wide use
Eli Lilly's treatment for early Alzheimer's was deemed too expensive for wide use by UK's cost-effectiveness body on ...
England’s Drug-Cost Watchdog Rejects Eli Lilly’s Alzheimer’s Drug
Regulator cited significant uncertainties about the drug’s benefits, as well as the high costs to treat its severe side ...
Grays Harbor Daily News2h
Aberdeen sweeps W.F. West on Senior Night
Playing in front of a Senior Night crowd in the midst of its best season in decades, the Bobcats (9-3 overall, 6-1 1A ...
UK regulator approves second Alzheimer's drug in months but government won't pay for it
Britain’s drug regulator approved the Alzheimer’s drug Kisunla on Wednesday, but the government won’t be paying for it after ...
Lilly's weight loss drug shortage deemed over, but hurdles remain
Some patients fear tirzepatide, sold by Eli Lilly under the brand names Zepbound and Mounjaro, will be hard to get and ...
Eli Lilly’s Alzheimer’s drug donanemab rejected for NHS use
The U.K. watchdog declines to endorse Eli Lilly's Alzheimer's drug donanemab, citing lack of value for the NHS and ...
Dunfermline Press4h
Alzheimer’s drug rejected for widespread use by NHS spending watchdog
A new Alzheimer’s drug has been rejected for widespread use in the health service in England after the health spending watchdog said it “does not currently demonstrate value for the NHS”. The news ...